SLC5A2 and diabetic kidney disease: An analysis of these topics may be relevant in the perspective of long-term exposure to these drugs, which appears all the more important considering that ongoing clinical trials are currently testing the efficacy and safety of SGLT2 inhibition in CKD patients with or without DKD [64].